195 related articles for article (PubMed ID: 36765430)
1. Cellular senescence in the response of HR
Klapp V; Buqué A; Bloy N; Sato A; Yamazaki T; Zhou XK; Formenti SC; Galluzzi L; Petroni G
J Transl Med; 2023 Feb; 21(1):110. PubMed ID: 36765430
[TBL] [Abstract][Full Text] [Related]
2. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.
Maskey RS; Wang F; Lehman E; Wang Y; Emmanuel N; Zhong W; Jin G; Abraham RT; Arndt KT; Myers JS; Mazurek A
Cell Cycle; 2021 Jan; 20(1):65-80. PubMed ID: 33356791
[TBL] [Abstract][Full Text] [Related]
3. Protective role of cytoplasmic p21Cip1/Waf1 in apoptosis of CDK4/6 inhibitor-induced senescence in breast cancer cells.
Kartika ID; Kotani H; Iida Y; Koyanagi A; Tanino R; Harada M
Cancer Med; 2021 Dec; 10(24):8988-8999. PubMed ID: 34761877
[TBL] [Abstract][Full Text] [Related]
4. Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells.
Gallanis GT; Sharif GM; Schmidt MO; Friedland BN; Battina R; Rahhal R; Davis JE; Khan IS; Wellstein A; Riegel AT
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980794
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
6. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
8. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts.
Stein GH; Drullinger LF; Soulard A; Dulić V
Mol Cell Biol; 1999 Mar; 19(3):2109-17. PubMed ID: 10022898
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
Alcorta DA; Xiong Y; Phelps D; Hannon G; Beach D; Barrett JC
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13742-7. PubMed ID: 8943005
[TBL] [Abstract][Full Text] [Related]
10. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER
Petroni G; Buqué A; Yamazaki T; Bloy N; Liberto MD; Chen-Kiang S; Formenti SC; Galluzzi L
Clin Cancer Res; 2021 Apr; 27(7):1855-1863. PubMed ID: 33495311
[TBL] [Abstract][Full Text] [Related]
12. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib-induced autophagy and senescence in gastric cancer cells.
Valenzuela CA; Vargas L; Martinez V; Bravo S; Brown NE
Exp Cell Res; 2017 Nov; 360(2):390-396. PubMed ID: 28947133
[TBL] [Abstract][Full Text] [Related]
14. Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the
Alsuraih M; O'Hara SP; Woodrum JE; Pirius NE; LaRusso NF
JHEP Rep; 2021 Jun; 3(3):100250. PubMed ID: 33870156
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometry-assisted quantification of cell cycle arrest in cancer cells treated with CDK4/6 inhibitors.
Klapp V; Bloy N; Jiménez-Cortegana C; Buqué A; Petroni G
Methods Cell Biol; 2024; 181():197-212. PubMed ID: 38302240
[TBL] [Abstract][Full Text] [Related]
16. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological CDK4/6 inhibition reveals a p53-dependent senescent state with restricted toxicity.
Wang B; Varela-Eirin M; Brandenburg SM; Hernandez-Segura A; van Vliet T; Jongbloed EM; Wilting SM; Ohtani N; Jager A; Demaria M
EMBO J; 2022 Mar; 41(6):e108946. PubMed ID: 34985783
[TBL] [Abstract][Full Text] [Related]
18. Melanin accumulation accelerates melanocyte senescence by a mechanism involving p16INK4a/CDK4/pRB and E2F1.
Bandyopadhyay D; Medrano EE
Ann N Y Acad Sci; 2000 Jun; 908():71-84. PubMed ID: 10911949
[TBL] [Abstract][Full Text] [Related]
19. Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.
Inao T; Kotani H; Iida Y; Kartika ID; Okimoto T; Tanino R; Shiba E; Harada M
Cancer Sci; 2019 Sep; 110(9):2690-2699. PubMed ID: 31250942
[TBL] [Abstract][Full Text] [Related]
20. Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence.
Carpintero-Fernández P; Borghesan M; Eleftheriadou O; Pan-Castillo B; Fafián-Labora JA; Mitchell TP; Yuste A; Ogrunc M; Nightingale TD; Mayan M; O'Loghlen A
Cell Death Dis; 2022 Feb; 13(2):163. PubMed ID: 35184131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
